News and Events
March 2020 - As part of our activity in the drug development market, we join the fight against COVID-19 by developing assays for testing novel anti viral drugs.
For more information click here
On November 25th, we had the great pleasure of launching the first OpenScreen Workshop in Israel! The meeting was organized by DR. Haim Barr, the Weizmann Institute of Science; Dr. Ludmila Buzhansky, Tel-Aviv University; Dr. Ela Strauss, Ministry of Science and Technology and Smart Assays' CEO, Dr.Raphael Mayer, the sole representative of the Israeli Biotech industry.
During the workshop Dr. Ronny Peri Naor, PhD, head of our bioanalytical unit spoke to European and local professionals at the Weitzman Institute of Science, and presented a short presentation titled "Walking through the 'crisis of reproducibility' – the investor perspective", which demonstrated the unique role we play in reducing investors risk in early stage investments.
We would like to thank Dr. Haim Barr for a successful collaboration!
Some of our Success
September 2019 - celebrating the New Jewish Year with a fun and challenging escape room followed by a great toast for an even greater year! Shana Tova!!
1st ISR-Openscreen Workshop - "Bringing Together Small Molecules and Biology
We are happy to be able to bring about our 20 years' experience in HTS assay development to the collaborative effort of the 1st ISR-Openscreen Workshop "Bringing Together Small Molecules and Biology". As part of the organization committee we are very pleased to invite you to take part - If you working on screening or developing molecules for biological applications – this is the place to be!
Looking forward seeing you
December 2018 - Smart Assays in the Israeli news (Hebrew)
Dr Raphael Mayer gave his professional opinion regarding the benefits of R&D services for biotechnology & pharmaceutical companies.
Link to the article from Globes
November 2018 - A great collaboration with BioSight - Innovative Cancer Therapeutics
September 2017- Smart Assays & Replicor collaboration:
Smart Assays is engaged in numerous Mode of Action (MOA) studies in collaboration with pharmaceutical company’s partners. Our successes are usually confidential, but today we are proud to share results from our recent study, performed in collaboration with our partners from Quebec - Replicor Inc., a clinical-stage company focused on developing novel NUCLEIC ACID-BASED POLYMERS (NAPs), to fight HBV and HDV. The study, performed at Smart Assays, revealed a novel model for NAPs interactions with small and large hepatitis delta antigen (HDAg), and was presented at “HBV International Meeting 2017” in Washington DC, U.S.A. https://lnkd.in/gr4Qrrs
February 2017- Smart Assay acquires ISO 9001:2015 Certification:
Smart Assays are proud to announce that we have received the latest ISO 9001:2015 certification, for our Quality Management System of assay development, in the fields of biochemistry and histopathology services (following an extensive audit conducted by SII-QCD).
The ISO 9001:2015 certification is a testimony of our commitment to deliver services and solutions of the highest quality. The ISO 9001:2015 quality system stresses continual improvement, client satisfaction, and regulatory compliance while providing a structure for companies to work on.
With our efforts focused on quality assurance and innovative solutions, we look forward to bringing you even more comprehensive, precise-to-need services, in the months and years to come.
November 2016 - EU project OLEUM: Assuring the quality and authenticity of olive oil
Smart Assays Biotechnologies Ltd., a high-end R&D service company specializing in assay development and research histopathology for biotech and pharma industries, announced today its participation in a consortium for research in assuring the quality and authenticity of olive oil within the EU Horizon 2020 Program for Research and Innovation. Twenty partners covering fifteen countries that bring together competences from food analysis, food legislation, industrial equipment engineering, bioinformatics, communication and knowledge exchange will develop new and improve existing analytical methods for detecting olive oil frauds.
Smart Assays Biotechnologies from Israel is the only entity in OLEUM consortium, with no background in the food industry however it has a
prominent track record in drug discovery, release tests and mechanism of action studies for biotech companies, and will focus its efforts to discover novel methodologies in olive oil related assays. The consortium will receive a grant of approximately 5 million Euros for the program.
For more details on the consortium visit:
December 2014 - Smart Assays 10 year anniversary
Yes, its true, Smart Assays was founded 10 years ago, and here we are celebrating!